CellSource Returns to Quarterly Profit but Keeps Forecast for Full-Year Loss

CellSource Co., Ltd. ( (JP:4880) ) has provided an update.

CellSource reported consolidated net sales of ¥860 million for the three months ended January 31, 2026, a modest 1.3% year-on-year increase, and swung to an operating and ordinary profit of ¥59 million with profit attributable to owners of parent at ¥33 million. The return to profitability contrasts with losses a year earlier, while basic earnings per share recovered to ¥1.70 and the equity-to-asset ratio remained high at 84.7%, underscoring a relatively sound balance sheet despite slightly lower total assets.

The company maintained its dividend plan of paying no interim or year-end dividends for the fiscal year ending October 31, 2026, after having paid a ¥5.00 year-end dividend in the previous fiscal year. Management also kept its full-year forecast unchanged, projecting a 7.9% decline in net sales to ¥3,418 million and a return to a net loss with basic earnings per share of negative ¥6.90, signaling expectations of profit pressure over the full year despite the strong first-quarter turnaround and suggesting ongoing challenges for shareholders looking for stable earnings and dividends.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen377.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

More about CellSource Co., Ltd.

CellSource Co., Ltd. is a Tokyo Stock Exchange-listed company operating under Japanese GAAP in the healthcare and biotech-related services sector. The company focuses on regenerative medicine–related businesses, providing specialized cell-processing and related solutions to medical institutions and other clients in Japan.

Average Trading Volume: 104,577

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.58B

Find detailed analytics on 4880 stock on TipRanks’ Stock Analysis page.